Overview
Kingmed Diagnostics
?
Yaoming Liang
See more contacts
Medical and Diagnostic Laboratories
,
Ambulatory Health Care Services
,
Health Care and Social Assistance
,
Medical laboratories
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
?
Actual
?
Actual
$992.28 million
Actual
-15.81%
$10,391
DEC
?
?
Shanghai:603882
Contacts
Get in Touch with 14 Principals*
-
Yaoming LiangDirector-General
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$992.28 million
USD
Actual
1 USD = 7.2455 CNY
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $125 | $170 | $269 |
| Net Investing Cash | -$63 | -$88 | -$117 |
| Net Financing Cash | -$67 | -$147 | -$120 |
| Net Change in Cash | -$5 | -$64 | $32 |
| Cash at Beginning of Period | $338 | $401 | $364 |
| Cash at End of Period | $334 | $338 | $401 |
| Capital Expenditure | -$62 | -$99 | -$116 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $336 | $339 | $404 |
| Accounts Receivable | $607 | $736 | $970 |
| Inventories | $27 | $34 | $56 |
| Other Current Assets | $40 | $31 | $41 |
| Asset Summary | |||
| Total Current Assets | $1,010 | $1,141 | $1,471 |
| Tangible Fixed Assets | $272 | $318 | $306 |
| Intangible Assets | $24 | $21 | $21 |
| Total Assets | $10,392 | $11,768 | $13,893 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $237 | $285 | $412 |
| Short-Term Debt | $0 | $0 | $ |
| Other Current Liabilities | $71 | $86 | $220 |
| Liability Summary | |||
| Total Current Liabilities | $308 | $371 | $632 |
| Long-Term Debt | $71 | $37 | $20 |
| Other Long-Term Liabilities | $ | $ | $ |
| Total Liabilities | $403 | $444 | $692 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $64 | $65 | $64 |
| Retained Earnings | $748 | $857 | $883 |
| Equity Summary | |||
| Total Equity | $1,011 | $1,154 | $1,192 |
| Shares Outstanding | 463,258,275 | 468,771,275 | 467,138,775 |